Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Core Insights - The Bax24 Phase III trial results indicate that baxdrostat significantly reduces ambulatory 24-hour average systolic blood pressure (SBP) compared to placebo at 12 weeks [1] Efficacy - Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo in addition to standard care [1] - The efficacy of baxdrostat was consistent throughout the 24-hour period, including early morning measurements [1]